Chris Ashwood
@cashwood.proteaglyco.com
Director of Protea Glycosciences
Accelerating glycoscience research
Accelerating glycoscience research
This enhanced MS2 quality enabled structural analysis of gastric mucins from three different species, highlighting the structural elucidation enabled by the approach.
Bonus: We also monitor the modified amino acid, giving us 2x the specificity (glycan + amino acid).
Happy to answer any questions!
Bonus: We also monitor the modified amino acid, giving us 2x the specificity (glycan + amino acid).
Happy to answer any questions!
November 26, 2025 at 6:43 AM
This enhanced MS2 quality enabled structural analysis of gastric mucins from three different species, highlighting the structural elucidation enabled by the approach.
Bonus: We also monitor the modified amino acid, giving us 2x the specificity (glycan + amino acid).
Happy to answer any questions!
Bonus: We also monitor the modified amino acid, giving us 2x the specificity (glycan + amino acid).
Happy to answer any questions!
We need high quality MS2 to discriminate isomers (either structural or compositional).
The higher charge states, enabled by supercharging, allow us to decipher structure and verify composition.
The higher charge states, enabled by supercharging, allow us to decipher structure and verify composition.
November 26, 2025 at 6:39 AM
We need high quality MS2 to discriminate isomers (either structural or compositional).
The higher charge states, enabled by supercharging, allow us to decipher structure and verify composition.
The higher charge states, enabled by supercharging, allow us to decipher structure and verify composition.
We recently introduced a new mobile phase for native glycan analysis. Now, we find the same reagents supercharge O-glycans, giving us up to 50% higher charge states.
Now, to exploit it...
Now, to exploit it...
November 26, 2025 at 6:03 AM
We recently introduced a new mobile phase for native glycan analysis. Now, we find the same reagents supercharge O-glycans, giving us up to 50% higher charge states.
Now, to exploit it...
Now, to exploit it...
Oxidatively released O-glycans grant additional information compared to released glycans, specifically, which amino acid is modified.
The problem? The reducing ends (glycolic or lactic acid) fix a charge on the reducing end, drastically reducing singly charged MS2 quality.
The problem? The reducing ends (glycolic or lactic acid) fix a charge on the reducing end, drastically reducing singly charged MS2 quality.
November 26, 2025 at 6:00 AM
Oxidatively released O-glycans grant additional information compared to released glycans, specifically, which amino acid is modified.
The problem? The reducing ends (glycolic or lactic acid) fix a charge on the reducing end, drastically reducing singly charged MS2 quality.
The problem? The reducing ends (glycolic or lactic acid) fix a charge on the reducing end, drastically reducing singly charged MS2 quality.
As an early tester of the column, I was very satisfied with its ability to resolve glycan structural isomers.
November 20, 2025 at 1:31 PM
As an early tester of the column, I was very satisfied with its ability to resolve glycan structural isomers.
An insightful patent, just from the drawings alone:
ELECTRO SPRAY IONIZATION WITH CONDUCTIVE PEEK VOLTAGE APPLICATION
patentscope.wipo.int/search/en/de...
- Features an exchangeable emitter for prolonged column lifetime
- Replacing the metal aspect of the emitter with carbon makes it biocompatible
ELECTRO SPRAY IONIZATION WITH CONDUCTIVE PEEK VOLTAGE APPLICATION
patentscope.wipo.int/search/en/de...
- Features an exchangeable emitter for prolonged column lifetime
- Replacing the metal aspect of the emitter with carbon makes it biocompatible
November 18, 2025 at 12:33 PM
An insightful patent, just from the drawings alone:
ELECTRO SPRAY IONIZATION WITH CONDUCTIVE PEEK VOLTAGE APPLICATION
patentscope.wipo.int/search/en/de...
- Features an exchangeable emitter for prolonged column lifetime
- Replacing the metal aspect of the emitter with carbon makes it biocompatible
ELECTRO SPRAY IONIZATION WITH CONDUCTIVE PEEK VOLTAGE APPLICATION
patentscope.wipo.int/search/en/de...
- Features an exchangeable emitter for prolonged column lifetime
- Replacing the metal aspect of the emitter with carbon makes it biocompatible
To use it, it's best to search for the instrument model and work from there.
Here's an example of all Orbitrap Astral (Zoom) tenders with purchase values:
The $1 is likely a placeholder, but MPI may not be.
These can also include LC, service contracts, etc, so approximation at best
Here's an example of all Orbitrap Astral (Zoom) tenders with purchase values:
The $1 is likely a placeholder, but MPI may not be.
These can also include LC, service contracts, etc, so approximation at best
November 10, 2025 at 12:21 PM
To use it, it's best to search for the instrument model and work from there.
Here's an example of all Orbitrap Astral (Zoom) tenders with purchase values:
The $1 is likely a placeholder, but MPI may not be.
These can also include LC, service contracts, etc, so approximation at best
Here's an example of all Orbitrap Astral (Zoom) tenders with purchase values:
The $1 is likely a placeholder, but MPI may not be.
These can also include LC, service contracts, etc, so approximation at best
New TMT Tribrid from Thermo for #ASMS2026 (public info)
- IRMPD is the new UPVD
- IRMPD with TMT boosts reporter intensity by up to 240% without affecting quant
- New resolutions -> Down to 1k res, with an associated loss of signal, but at least it looks faster!
- Improved proton transfer reaction
- IRMPD is the new UPVD
- IRMPD with TMT boosts reporter intensity by up to 240% without affecting quant
- New resolutions -> Down to 1k res, with an associated loss of signal, but at least it looks faster!
- Improved proton transfer reaction
November 6, 2025 at 7:18 AM
New TMT Tribrid from Thermo for #ASMS2026 (public info)
- IRMPD is the new UPVD
- IRMPD with TMT boosts reporter intensity by up to 240% without affecting quant
- New resolutions -> Down to 1k res, with an associated loss of signal, but at least it looks faster!
- Improved proton transfer reaction
- IRMPD is the new UPVD
- IRMPD with TMT boosts reporter intensity by up to 240% without affecting quant
- New resolutions -> Down to 1k res, with an associated loss of signal, but at least it looks faster!
- Improved proton transfer reaction
A popular post on LinkedIn related to the reliability of current state-of-the-art instrumentation. #teammassspec
Related, anyone know how many more scientists are employed in marketing compared to R&D?
Related, anyone know how many more scientists are employed in marketing compared to R&D?
November 3, 2025 at 7:20 AM
A popular post on LinkedIn related to the reliability of current state-of-the-art instrumentation. #teammassspec
Related, anyone know how many more scientists are employed in marketing compared to R&D?
Related, anyone know how many more scientists are employed in marketing compared to R&D?
#glycotime #microsky
"host-cell directed genome-wide screen for host factors required for rhoptry discharge from Toxoplasma gondii, the causative agent of toxoplasmosis. The screen identified host N-glycosylation and cholesterol biosynthesis as pathways required for normal rhoptry discharge."
"host-cell directed genome-wide screen for host factors required for rhoptry discharge from Toxoplasma gondii, the causative agent of toxoplasmosis. The screen identified host N-glycosylation and cholesterol biosynthesis as pathways required for normal rhoptry discharge."
October 22, 2025 at 1:42 PM
#glycotime #microsky
"host-cell directed genome-wide screen for host factors required for rhoptry discharge from Toxoplasma gondii, the causative agent of toxoplasmosis. The screen identified host N-glycosylation and cholesterol biosynthesis as pathways required for normal rhoptry discharge."
"host-cell directed genome-wide screen for host factors required for rhoptry discharge from Toxoplasma gondii, the causative agent of toxoplasmosis. The screen identified host N-glycosylation and cholesterol biosynthesis as pathways required for normal rhoptry discharge."
New Sciex patent -> negative Electron Transfer Dissociation (nETD) on a ZenoTOF.
Looks like they're solidly aiming for the biopharma market on this next ZenoTOF (9600?), specifically, oligonucleotides.
patentscope.wipo.int/search/en/de...
Looks like they're solidly aiming for the biopharma market on this next ZenoTOF (9600?), specifically, oligonucleotides.
patentscope.wipo.int/search/en/de...
October 21, 2025 at 11:00 AM
New Sciex patent -> negative Electron Transfer Dissociation (nETD) on a ZenoTOF.
Looks like they're solidly aiming for the biopharma market on this next ZenoTOF (9600?), specifically, oligonucleotides.
patentscope.wipo.int/search/en/de...
Looks like they're solidly aiming for the biopharma market on this next ZenoTOF (9600?), specifically, oligonucleotides.
patentscope.wipo.int/search/en/de...
Sadly, I have to confirm that ChatGPT was poisoned by your earlier searches.
I tried the same prompt and it said they should use a NotATof mass analyser, which I made up as the name for the Astral.
Had a completely false backstory for it too!
I tried the same prompt and it said they should use a NotATof mass analyser, which I made up as the name for the Astral.
Had a completely false backstory for it too!
October 16, 2025 at 3:49 PM
Sadly, I have to confirm that ChatGPT was poisoned by your earlier searches.
I tried the same prompt and it said they should use a NotATof mass analyser, which I made up as the name for the Astral.
Had a completely false backstory for it too!
I tried the same prompt and it said they should use a NotATof mass analyser, which I made up as the name for the Astral.
Had a completely false backstory for it too!
Hey, it gets some things right!
October 16, 2025 at 2:31 PM
Hey, it gets some things right!
Anyone looking forward to purchasing an LC-MS co-developed by OpenAI?
October 16, 2025 at 1:57 PM
Anyone looking forward to purchasing an LC-MS co-developed by OpenAI?
Spec sheet is pretty barebones (technically not even a spec sheet) but the tech notes has more info:
October 13, 2025 at 11:19 AM
Spec sheet is pretty barebones (technically not even a spec sheet) but the tech notes has more info:
Wrapping up the 2025 Skyline Online Small Molecule course! Fantastic instructors and presenters, including Haley from the Baker lab with an insightful ion mobility crash course.
Great discussion and interaction from participants this year—looking forward to next year! #teammassspec
Great discussion and interaction from participants this year—looking forward to next year! #teammassspec
October 10, 2025 at 7:20 PM
Wrapping up the 2025 Skyline Online Small Molecule course! Fantastic instructors and presenters, including Haley from the Baker lab with an insightful ion mobility crash course.
Great discussion and interaction from participants this year—looking forward to next year! #teammassspec
Great discussion and interaction from participants this year—looking forward to next year! #teammassspec
Very excited to kick off the annual Skyline Online 2025 Small Molecule course with a keynote lecture by Gary Patti @gjpattij.bsky.social.
Showing how his lab and collaborators are advancing mass spectrometry to achieve parity with sequencing techs, supported by Skyline!
Showing how his lab and collaborators are advancing mass spectrometry to achieve parity with sequencing techs, supported by Skyline!
October 8, 2025 at 1:57 PM
Very excited to kick off the annual Skyline Online 2025 Small Molecule course with a keynote lecture by Gary Patti @gjpattij.bsky.social.
Showing how his lab and collaborators are advancing mass spectrometry to achieve parity with sequencing techs, supported by Skyline!
Showing how his lab and collaborators are advancing mass spectrometry to achieve parity with sequencing techs, supported by Skyline!
This is what LC-MS proteomics is up against.
Generation of a knock-out cell line + western blot VS targeted LC-MS proteomics.
Pretty sure one is cheaper, faster and more reproducible than the other.
Here's that protein from the GPMDB.
Generation of a knock-out cell line + western blot VS targeted LC-MS proteomics.
Pretty sure one is cheaper, faster and more reproducible than the other.
Here's that protein from the GPMDB.
October 3, 2025 at 11:03 AM
This is what LC-MS proteomics is up against.
Generation of a knock-out cell line + western blot VS targeted LC-MS proteomics.
Pretty sure one is cheaper, faster and more reproducible than the other.
Here's that protein from the GPMDB.
Generation of a knock-out cell line + western blot VS targeted LC-MS proteomics.
Pretty sure one is cheaper, faster and more reproducible than the other.
Here's that protein from the GPMDB.
Confirmed by Thermo marketing. So feel free to let your sales reps know that you want a custom Astral Zoom.
October 2, 2025 at 11:01 AM
Confirmed by Thermo marketing. So feel free to let your sales reps know that you want a custom Astral Zoom.
Without #2, a lower ion count is needed just to be sure that the full MS range is scanned, but with more accurate ion counts, you can go to the max S/N without losing ions on the edges.
This could also work for the Orbitrap Astral.
Bonus: DIAPASEF on Thermo - patentscope.wipo.int/search/en/de...
This could also work for the Orbitrap Astral.
Bonus: DIAPASEF on Thermo - patentscope.wipo.int/search/en/de...
September 28, 2025 at 1:25 PM
Without #2, a lower ion count is needed just to be sure that the full MS range is scanned, but with more accurate ion counts, you can go to the max S/N without losing ions on the edges.
This could also work for the Orbitrap Astral.
Bonus: DIAPASEF on Thermo - patentscope.wipo.int/search/en/de...
This could also work for the Orbitrap Astral.
Bonus: DIAPASEF on Thermo - patentscope.wipo.int/search/en/de...
A new Tribrid next year, suggest two patents made public simultaneously, representing improved full Orbitrap scan range and more accurate Orbitrap ion measurement:
1. C-trap improvement from 15x lowest mass, to 40x lowest mass
2. Using the LIT to count ions for accurate AGC on the Orbitrap
1. C-trap improvement from 15x lowest mass, to 40x lowest mass
2. Using the LIT to count ions for accurate AGC on the Orbitrap
September 28, 2025 at 1:18 PM
A new Tribrid next year, suggest two patents made public simultaneously, representing improved full Orbitrap scan range and more accurate Orbitrap ion measurement:
1. C-trap improvement from 15x lowest mass, to 40x lowest mass
2. Using the LIT to count ions for accurate AGC on the Orbitrap
1. C-trap improvement from 15x lowest mass, to 40x lowest mass
2. Using the LIT to count ions for accurate AGC on the Orbitrap
Rumour is that Sciex are currently the lowest priced top-tier MS right now, with the 8600 coming in around $1 million USD.
They should make their money back in other ways (software subscriptions in particular), but if you want the cheapest, single cell-level MS, the 8600 is probably it.
They should make their money back in other ways (software subscriptions in particular), but if you want the cheapest, single cell-level MS, the 8600 is probably it.
September 26, 2025 at 1:41 PM
Rumour is that Sciex are currently the lowest priced top-tier MS right now, with the 8600 coming in around $1 million USD.
They should make their money back in other ways (software subscriptions in particular), but if you want the cheapest, single cell-level MS, the 8600 is probably it.
They should make their money back in other ways (software subscriptions in particular), but if you want the cheapest, single cell-level MS, the 8600 is probably it.
Seen in the wild, another limited edition Astral Zoom.
This time with white trim and 40% brighter ion inlet (obviously caused by the trim).
This time with white trim and 40% brighter ion inlet (obviously caused by the trim).
September 25, 2025 at 2:37 PM
Seen in the wild, another limited edition Astral Zoom.
This time with white trim and 40% brighter ion inlet (obviously caused by the trim).
This time with white trim and 40% brighter ion inlet (obviously caused by the trim).
Pretty cool update from GlycoScape:
Sugar-specific visualisation, based on the sugar type. Should help for hypothesis generation since you can plot each sugar type and compare.
Sugar-specific visualisation, based on the sugar type. Should help for hypothesis generation since you can plot each sugar type and compare.
September 25, 2025 at 5:21 AM
Pretty cool update from GlycoScape:
Sugar-specific visualisation, based on the sugar type. Should help for hypothesis generation since you can plot each sugar type and compare.
Sugar-specific visualisation, based on the sugar type. Should help for hypothesis generation since you can plot each sugar type and compare.
September 22, 2025 at 7:42 PM